AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Kiora Pharmaceuticals, Inc.
Video analysis: KPRX
All videosNo video analysis for this stock yet. Request one from our team.
News: KPRX
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies.
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Encinitas, Califfornia--(Newsfile Corp. - August 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today reported financial results for the second quarter ended June 30, 2026, and provided an update on its clinical pipeline of small-molecule therapies for retinal diseases and its corporate development activities. Second Quarter 2026 and Recent Highlights Advanced enrollment in the Phase 2 ABACUS-2 clinical trial of KIO-301 into the higher-dose cohort Continued enrollment in the higher-dose cohort of the Phase 2 KLARITY clinical trial of KIO-104 Ended the quarter with approximately $16.8 million in cash and short-term investments, providing an expected operating runway into late 2028 Secured a private placement for up to $24.0 million in gross proceeds, including $5.0 million received upfront, with the remaining proceeds contingent on the exercise of near-term milestone-based warrants KIO-301 "Patient demand for ABACUS-2 remains high as we have begun to enroll the higher 100 µg dose cohort," said Brian Strem, Ph.D.
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium. Presentation Details Date: Thursday, July 9, 2026 Time: 2:30 p.m.
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epileptiform Activity: KIO-300 is the active pharmaceutical ingredient of KIO-301, Kiora's ongoing Phase 2 clinical program in vision restoration in patients with gene mutation-agnostic Retinitis Pigmentosa Encinitas, California--(Newsfile Corp. - June 18, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA.
